Pharmafile Logo

Ruvise

Novartis day

Could Cosentyx free psoriasis patients from treatment?

One in five patients on the Novartis treatment remained symptom-free for a year

Polyphor appoints new chief medical and development officer

Dr Debra Baker joins the firm from Novartis

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

Novartis day

FDA approval for Kisqali sets up showdown with Ibrance

Novartis breast cancer therapy drug has been predicted to reach blockbuster status

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links